Cor Vasa 2008, 50(9):354-357

Treatment of very elderly hypertensives significantly reduces total mortality and the risk of death from stroke. Results of the HYVET trial

Jiří Widimský

Klinika kardiologie, Institut klinické a experimentální medicíny, Subkatedra kardiologie IPVZ, Praha, Česká republika

Until recently, it was not known whether treatment of hypertension in the very elderly had any beneficial effects. The Hypertension in the Very Elderly Trial (HYVET) is the first prospective, double-blind trial assessing the efficacy of anti-hypertensive therapy in this age group (80 years and older).
Overall, 3,845 patients with a mean age of 83.6 years were randomized either to a group receiving active therapy or one receiving placebo. The mean sitting blood pressure prior to therapy initiation was 173.0/90.8 mmHg. Active therapy included indapamide SR at a dose of 1.5mg. Perindopril at doses of 2mg or 4mg could be added to active therapy in cases where the target blood pressure levels of

Keywords: Hypertension in the very elderly; HYVET; Treatment of hypertension

Published: September 1, 2008  Show citation